Actualités - Page 2 sur 4 - Laborie

Urologie et urogynécologie

Laborie Announces First Procedures in ENDURE 1 Study with the Optilume® Ureteric Drug-Coated Balloon

Non classifié(e)

Laborie Appoints Chris Smith as Chief Executive Officer

Laborie Medical Technologies Corp., a global leader in medical technology, today announced the appointment of Chris Smith as Chief Executive Officer, effective September 22, 2025. Smith succeeds Michael Frazzette, who announced his retirement last month.

Urologie et urogynécologie

Laborie’s Optilume® Drug-Coated Balloon for Stricture Secures Coverage from BCBS of Michigan

Effective July 1, 2025, Blue Cross Blue Shield of Michigan (BCBSM) has issued a new medical policy under CPT code 52284, extending coverage for Laborie Medical Technologies’ Optilume® Urethral Drug-Coated Balloon for Stricture to eligible Commercial HMO members. This new coverage reinforces Laborie’s ongoing commitment to enhancing patient outcomes through wider access to evidence-based medical technologies.

Urologie et urogynécologie

Three-Year Data from ROBUST III Confirms Long-Term Durability of Optilume® Drug-Coated Balloon for Recurrent Urethral Strictures

Laborie Medical Technologies Corp. (Laborie), a global leader in diagnostic and therapeutic urology, announced the publication of three-year outcomes from the ROBUST III randomized controlled trial in the Journal of Endourology. The results underscore the long-term durability and safety of the Optilume® Drug-Coated Balloon (DCB) as a minimally invasive treatment for recurrent anterior urethral strictures in men.

Urologie et urogynécologie

Optilume Drug-Coated Balloon Shows Long-Term Efficacy for Urethral Strictures: Five-Year Data Published in the Journal of Urology

Optilume BPH CPT Code

Non classifié(e) |

Urologie et urogynécologie

Optilume® BPH Catheter System Issued Category 1 CPT Code by American Medical Association

Obstétrique, gynécologie et néonatale

Laborie Medical Technologies to Invest in Medical Technology Start-Up Novocuff

Laborie announced its investment in Novocuff, an early-stage medical technology company headquartered in Mountain View, CA.

Gastroentérologie

Laborie Introduces Solar Compact System and Solar Anorectal Manometry Catheter for Enhanced Gastrointestinal Diagnostics

Laborie is proud to introduce the Solar Compact System and Solar Anorectal Manometry Catheter, the first disposable HRAM catheter on the market.

Urologie et urogynécologie

Laborie Unveils Positive Study Results for Optilume® BPH Catheter System

Laborie announced positive 2-year and 5-year results from studies for its Optilume® BPH Catheter System.

Urologie et urogynécologie

NHS England Reimburses Optilume® Urethral Drug Coated Balloon as Part of the Specialised Services Device Programme

Laborie welcomed the inclusion of Optilume® Urethral Drug-Coated Balloon (DCB) into the National Health Service (NHS) Specialized Services Device Programme (SSDP) as of April 1, 2024.

Page 2 sur 4«123 4 »